Instrument Inactif

Communiqués XpresSpa Group Inc Nasdaq

Actions

US98420U1097

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

XWELL Opens New XpresSpa Location at Philadelphia International Airport	17/06	AQ
XWELL Introduces New Esthetic Facial Services to Naples Wax Center Locations	05/06	AQ
XWELL Continues to Innovate in Airport Wellness Space with New Massage Solutions: Introducing Ceragem V6 in select XpresSpa® Locations in US	23/05	AQ
XWELL, Inc. Reports First Quarter 2024 Results	15/05	AQ
XWELL - XpresSpa Introduces IV Hydration Drip Therapy at Miami International Airport; Pilot program designed to expand service offerings and drive revenue growth	03/05	AQ
XpresSpa Introduces IV Hydration Drip Therapy at Miami International Airport	02/05	AQ
XWELL, Inc. Reports Fiscal Year 2023 Results	16/04	AQ
XWELL, Inc. to Report Fiscal Year 2023 Financial Results on Tuesday, April 16, 2024	16/04	AQ
XWELL : Non-Reliance on Previously Issued Financial Report - Form 8-K	12/04	PU
XWELL, Inc. Plans to File Form 12b-25 to Extend Filing Date of its Form 10-K	01/04	AQ
Ginkgo Bioworks - CDC Traveler-based Genomic Surveillance Program to Expand to Two New US International Airports in Miami and Chicago	13/03	AQ
CDC Traveler-based Genomic Surveillance Program to Expand to Two New US International Airports in Miami and Chicago	12/03	AQ
XWELL Advances Expansion Plan Outside the Airport with Three New Naples Wax and Skin Care Locations	14/02	AQ
Self-serve XpressSpa coming to New York City’s Penn Station	05/01	AQ
XWELL Announces Plans to Open an XpresSpa in THE PENN DISTRICT	04/01	AQ
XWELL Appoints Veteran Consumer & Wellness Entrepreneur Gaëlle Wizenberg to its Board of Directors	15/12	AQ
XpresSpa Introduces Clockwork Robotic Manicures at Harry Reid International Airport in Las Vegas	11/12	AQ
XWELL Opens New XpresSpa Location in Abu Dhabi International Airport	15/11	AQ
XWELL, Inc. Reports Third Quarter 2023 Results	14/11	AQ
Ginkgo Bioworks and XWELL Implement Expanded CDC Traveler-based Genomic Surveillance Program to Test for More than 30 Known Pathogens	06/11	PR

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués XpresSpa Group Inc Nasdaq

Actions

US98420U1097

Communiqués

Filtres